|
|
|
| Rifampicin and isoniazid resistance among pulmonary tuberculosis patients in Luohu District from 2012 to 2022 |
| TANG Xiaofen, QIN Daoxin, JIN Fengxia, TIAN Yuan, ZOU Yongxia, SHEN Yurong, LIU Yao, XIE Xiuchai
|
| Luohu District Chronic Disease Hospital, Shenzhen, Guangdong 518020, China |
|
|
|
|
Abstract Objective To investigate the resistance to rifampicin and isoniazid and the changing trends among patients with pulmonary tuberculosis in Luohu District, Shenzhen City, Guangdong Province from 2012 to 2022, so as to provide insights into improving drug-resistant pulmonary tuberculosis control and prevention strategies. Methods Basic information, treatment classification and drug resistance data of patients with pulmonary tuberculosis and positive pathogenic detection in Luohu District from 2012 to 2022 were collected through the Tuberculosis Surveillance System of Chinese Disease Prevention and Control Information System, and resistance rates of rifampicin and isoniazid and the changing trends were analyzed. Results A total of 2 126 patients with pulmonary tuberculosis were collected and had a median age of 34 (interquartile range, 25) years, including 1 334 males (62.75%) and 792 females (37.25%). There were 302 patients with drug-resistance in Luohu District from 2012 to 2022, with a resistance rate of 14.21%. Among them, 60 patients were monoresistant to rifampicin (2.82%), 113 patients were monoresistant to isoniazid (5.32%), and 129 patients were multidrug resistant (6.07%). The rate of rifampicin monoresistance showed a downward trend from 2012 to 2022, while the rate of multidrug resistance showed an upward trend (both P<0.05). There was no significant tendency in the rate of isoniazid monoresistance (P>0.05). The rate of multidrug resistance among patients without Shenzhen residence was higher than that among patients with Shenzhen residence; the rates of rifampicin resistance and multidrug resistance among retreated patients were higher than those among treatment-naïve patients (all P<0.05). Conclusions The rate of rifampicin monoresistance appeared a downward trend and the rate of multidrug resistance appeared an upward trend among patients with pulmonary tuberculosis in Luohu District from 2012 to 2022. Attention should be given to non-Shenzhen residence and retreated patients.
|
|
Received: 02 February 2024
Revised: 09 April 2024
Published: 20 June 2024
|
|
|
|
|
|
[1] LANGE C,DHEDA K,CHESOV D,et al.Management of drug-resistant tuberculosis[J].Lancet,2019,394(10202):953-966.
[2] World Health Organization.Global Tuberculosis Report 2023[R].Geneva:WHO,2023.
[3] MALENFANT J H,BREWER T F.Rifampicin mono-resistant tuberculosis-a review of an uncommon but growing challenge for global tuberculosis control[J].Open Forum Infect Dis,2021,8(2):1-6.
[4] ALEMU A,BITEW Z W,DIRIBA G,et al.Poor treatment outcome and associated risk factors among patients with isoniazid mono-resistant tuberculosis:a systematic review and meta-analysis[J].PLoS One,2023,18(7):1-22.
[5] 中国防痨协会.耐药结核病化学治疗指南(2019年简版)[J].中国防痨杂志,2019,41(10):1025-1073.
[6] 中国防痨协会基础专业委员会.结核病诊断实验室检验规程[M].北京:中国教育文化出版社,2006.
[7] World Health Organization.WHO policy statement:molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis[R].Geneva:WHO,2008.
[8] LECAI J,MIJITI P,CHUANGYUE H,et al.Predictors and trends of MDR/RR-TB in Shenzhen China:a retrospective 2012-2020 period analysis[J].Infect Drug Resist,2021,14:4481-4491.
[9] 王云霞,郑娟娟,张娟娟,等.2011—2018年宝安区肺结核患者耐多药的影响因素分析[J].预防医学,2021,33(7):701-703.
[10] 方世林,王芸,禄晓龙,等.中国耐多药结核病患者治疗结局的Meta分析[J].中国循证医学杂志,2021,21(11):1323-1331.
[11] ROYCE S,FALZON D,VAN WEEZENBEEK C,et al.Multidrug resistance in new tuberculosis patients:burden and implications[J].Int J Tuberc Lung Dis,2013,17(4):511-513.
[12] 崔彩岩,曾令城,李于于,等.2014—2020年西安市利福平耐药肺结核流行趋势分析[J].现代预防医学,2021,48(14):2659-2663.
[13] ZHANG J Y,GOU H M,HU X J,et al.Status of drug-resistant tuberculosis in China:a systematic review and meta-analysis[J].Am J Infect Control,2016,44(6):671-676.
[14] LIU L,ZHAO X J,WU X Y,et al.Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Hainan,China:from 2014 to 2019[J].BMC Microbiol,2021,21(1):1-11.
[15] 杨圆,邹霞,凌莉.应用传播动力学模型模拟我国人口流动情况对耐多药结核病发病率的影响[J].热带医学杂志,2022,22(7):1001-1005.
[16] 丰达星,张璐,吕宛玉,等.我国耐多药结核患者治疗依从性影响因素Meta分析[J].实用预防医学,2019,26(7):823-826.
[17] 高华强,卢巧玲,金法祥,等.绍兴市肺结核患者耐药特征分析[J].预防医学,2020,32(4):384-387.
[18] 吴玉姣,左小明,秦科宇,等.常州市老年肺结核患者利福平耐药分析[J].预防医学,2024,36(2):162-164,168.
[19] NSOFOR C A,JIANG Q,WU J,et al.Transmission is a noticeable cause of resistance among treated tuberculosis patients in Shanghai,China[J].Sci Rep,2017,7(1):1-6. |
|
|
|
